Efavirenz is an antiretroviral medication used to treat HIV. It is sold under the brand name Sustiva and is also one of the active ingredients in the combination tablet Atripla. Published laboratory research has found that efavirenz, or a metabolite it breaks down into, can trigger a false positive result on certain urine screening immunoassays for tetrahydrocannabinol (THC) and on some benzodiazepine screening immunoassays. This article explains what the research actually shows, why a screening result is never the final word, and how the confirmation and medical review officer process is designed to resolve exactly this kind of interference without requiring anyone to disclose a diagnosis to an employer.
Screening immunoassays versus confirmation testing
A urine drug test cup, dip card, or lab-based screen usually starts with an immunoassay. Immunoassays work by using antibodies that bind to a target drug or drug metabolite, and the test reports a result once the specimen crosses a set cutoff concentration. Antibodies are not perfectly selective. A compound that is structurally similar enough to the target can sometimes bind to the same antibody and push a specimen over the cutoff even though the actual target drug is not present. That is called cross reactivity, and it is the most common cause of a false positive screen.
Because immunoassays can cross react, a nonnegative screening result is a presumptive finding, not a diagnosis of drug use. Federal workplace testing programs and most private drug-free workplace policies require that any nonnegative immunoassay be sent for confirmation by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS). Confirmation methods identify and quantify the specific molecule, so a false positive caused by cross reactivity does not survive confirmation. The Substance Abuse and Mental Health Services Administration describes this screen and confirm structure, along with the role of the medical review officer, in its program guidance.
What the published research on efavirenz actually shows
Two laboratory studies, cited directly here because this is a documented and verifiable interference rather than an anecdote, describe efavirenz cross reactivity with THC immunoassays. A 2006 letter in Clinical Chemistry characterized how efavirenz carboxylic acid glucuronide, a metabolite of efavirenz, interfered with six commercial delta-9-THC immunoassays and produced false positive cannabinoid results in patients taking the medication who had not used marijuana, as reported in the study available through PubMed. A follow-up 2011 study in the Annals of Clinical Biochemistry confirmed efavirenz interference in urine THC screening immunoassays and is also indexed on PubMed. In both cases, confirmation testing by GC/MS or LC/MS did not detect the actual THC metabolite, which is exactly what a true false positive looks like once a specific chromatography method is applied.
A separate study published in Clinical Infectious Diseases found that efavirenz treatment was associated with false positive results on benzodiazepine screening immunoassays in a group of patients being monitored, a finding that is also indexed on PubMed. As with the cannabinoid interference, the mechanism is cross reactivity between efavirenz or its metabolites and the antibodies used in certain benzodiazepine immunoassay platforms, not an actual benzodiazepine in the specimen.
These findings are specific to THC and benzodiazepine immunoassays. There is no credible published cross reactivity evidence tying efavirenz to opiate, amphetamine, cocaine, or PCP immunoassays, and efavirenz is not part of any of those drug classes. The prescribing information for efavirenz-containing products, available through the National Library of Medicine's DailyMed label, lists efavirenz as a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for HIV-1 infection and does not describe it as having any pharmacologic relationship to cannabinoids or benzodiazepines.
Why a positive screen is never the end of the process
A nonnegative immunoassay result on a workplace or clinical drug screen does not get reported to an employer as a failed test. It goes to a medical review officer (MRO), a licensed physician trained to review laboratory results, verify legitimate medical explanations, and determine whether a result should be reported as positive, negative, or canceled. The MRO contacts the individual directly, in confidence, to ask about prescribed medications and, when needed, verifies the prescription with the pharmacy or prescribing clinician. The person does not have to tell the employer what the medication treats or disclose an HIV diagnosis. The MRO handles that conversation and the employer only receives the final determination, not the medical details behind it. SAMHSA's drug testing program resources describe this verification step and the confirmation requirement in detail.
This structure exists specifically so that a legitimate prescription, including treatment for a condition protected from workplace disclosure, does not turn into a false accusation. It also means nobody should ever be asked to explain a diagnosis to a supervisor or HR contact to clear a screening result. For a fuller walkthrough of how that review works end to end, see our explanation of the medical review officer process.
HIV medications and drug test panel notes
| Medication or class | Common brand examples | Panel interaction note | Confirmation route |
|---|---|---|---|
| Efavirenz (NNRTI) | Sustiva, combined in Atripla and Symfi products | Documented cross reactivity on some THC and benzodiazepine screening immunoassays | GC/MS or LC/MS clears the false positive |
| Other NNRTIs (doravirine, rilpivirine, etravirine) | Pifeltro, Edurant, Intelence | No credible published cross reactivity evidence located for standard drug test panels | Lab confirmation available if a screen is ever nonnegative |
| Integrase inhibitors | Tivicay, Biktarvy components, Isentress | No credible published cross reactivity evidence located for standard drug test panels | Lab confirmation available if a screen is ever nonnegative |
| Protease inhibitors | Norvir, Prezista, Reyataz | No credible published cross reactivity evidence located for standard drug test panels | Lab confirmation available if a screen is ever nonnegative |
| NRTIs | Tenofovir, emtricitabine, lamivudine products | No credible published cross reactivity evidence located for standard drug test panels | Lab confirmation available if a screen is ever nonnegative |
This table reflects what is published and verifiable as of this writing, not an exhaustive clinical review. Anyone with a question about a specific prescription and a specific test platform should raise it with the testing lab or the MRO rather than relying on a general list, because immunoassay reagents vary by manufacturer and by panel generation.
Confidentiality and nondiscrimination
HIV status is sensitive medical information, and nothing about the screening and confirmation process should require a person to reveal it to a supervisor, coworker, or HR staff member outside the MRO channel. Employers generally may not require disclosure of a specific diagnosis as a condition of resolving a drug test, and the Americans with Disabilities Act framework around medical confidentiality is one reason the MRO review exists as a buffer between a lab result and an employment decision. Employers and testing administrators who have questions about handling a nonnegative result involving a protected medical condition should consult legal counsel rather than make an independent call, since the specifics vary by situation.
What this means for testing programs
Programs that rely only on an instant cup or dip card result without a confirmation pathway have no way to catch this kind of cross reactivity. A sound program pairs an initial screening device, whether a multi-panel urine cup, a dip card, or an oral fluid collection, with a documented policy that routes every nonnegative screen to confirmation and MRO review before any result is reported as positive. American Screening Corporation supplies multi-panel drug test cups built for that screen-first, confirm-second workflow, with cutoffs that match standard laboratory confirmation thresholds. For background on how screening devices handle interfering substances generally, see our overview of benzodiazepine panel detection and its limits.
Frequently asked questions
Does efavirenz show up as a false positive for marijuana on a drug test?
Published laboratory studies have found that efavirenz, through a metabolite, can cross react with certain THC screening immunoassays and produce a nonnegative cannabinoid result in people who have not used marijuana. Confirmation testing by GC/MS or LC/MS resolves this because it identifies the actual molecule rather than relying on antibody binding.
Can efavirenz cause a false positive benzodiazepine result?
Yes. A published study found efavirenz treatment associated with false positive results on certain benzodiazepine screening immunoassays. As with the THC interference, lab confirmation distinguishes a true benzodiazepine finding from cross reactivity.
Does a nonnegative screen from efavirenz count as a failed drug test?
No. A screening immunoassay result is presumptive. It should go to confirmation testing and medical review officer review before anyone reports it as a positive result, and a verified prescription or a confirmation result that does not detect the substance resolves it.
Does someone taking efavirenz have to tell their employer they have HIV?
No. The medical review officer verifies prescriptions directly and confidentially with the individual and, if needed, the prescribing clinician or pharmacy. An employer generally receives only the final determination, not the underlying diagnosis.
Do other HIV medications cause the same false positives?
There is no credible published cross reactivity evidence for the other major antiretroviral classes, including integrase inhibitors, protease inhibitors, and most other NNRTIs, on standard drug test panels. The documented interference is specific to efavirenz on certain THC and benzodiazepine immunoassay platforms.
What should someone do if they get an unexpected positive screen while on efavirenz?
Report the current prescription to the collector or testing administrator and wait for the medical review officer to contact them directly. There is no need to explain the underlying condition, and confirmation testing is the step that actually sorts out a true result from cross reactivity.
This article is general information about drug testing science and process, not medical or legal advice. Anyone with questions about a specific test result or prescription should talk to their healthcare provider, the testing laboratory, or a qualified attorney.
